AU2020334194A1 - Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions - Google Patents

Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions Download PDF

Info

Publication number
AU2020334194A1
AU2020334194A1 AU2020334194A AU2020334194A AU2020334194A1 AU 2020334194 A1 AU2020334194 A1 AU 2020334194A1 AU 2020334194 A AU2020334194 A AU 2020334194A AU 2020334194 A AU2020334194 A AU 2020334194A AU 2020334194 A1 AU2020334194 A1 AU 2020334194A1
Authority
AU
Australia
Prior art keywords
group
compound
methyl
hydrogen
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020334194A
Other languages
English (en)
Inventor
Volker Adams
Siegfried Labeit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2020334194A1 publication Critical patent/AU2020334194A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020334194A 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions Abandoned AU2020334194A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19192107 2019-08-16
EP19192107.1 2019-08-16
PCT/EP2020/072911 WO2021032643A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Publications (1)

Publication Number Publication Date
AU2020334194A1 true AU2020334194A1 (en) 2022-02-24

Family

ID=67659191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020334194A Abandoned AU2020334194A1 (en) 2019-08-16 2020-08-14 Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions

Country Status (13)

Country Link
US (1) US12331042B2 (enExample)
EP (1) EP4013497B1 (enExample)
JP (1) JP2022544803A (enExample)
KR (1) KR20220047807A (enExample)
CN (1) CN114302881B (enExample)
AU (1) AU2020334194A1 (enExample)
BR (1) BR112022002769A2 (enExample)
CA (1) CA3144700A1 (enExample)
CL (1) CL2022000320A1 (enExample)
IL (1) IL290540A (enExample)
MX (1) MX2022002022A (enExample)
WO (1) WO2021032643A1 (enExample)
ZA (1) ZA202202863B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102823820B1 (ko) * 2022-09-01 2025-06-23 단국대학교 천안캠퍼스 산학협력단 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물
WO2024068809A1 (en) * 2022-09-30 2024-04-04 Société des Produits Nestlé S.A. Composition and method for treating muscle decline associated with renal disease or dysfunction
KR102995500B1 (ko) * 2024-11-07 2026-07-23 아주대학교산학협력단 근감소증의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200803016B (en) * 2005-09-29 2009-10-28 Elan Pharmaceuticals Inc Wyeth Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
US20140161729A1 (en) * 2011-04-07 2014-06-12 Cornell University Cofluorons and methods of making and using them
CN106822153B (zh) * 2011-06-06 2019-12-17 爱荷华大学研究基金会 用于抑制肌萎缩的方法
AU2014290368B2 (en) * 2013-07-18 2019-07-11 Baylor College Of Medicine Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
CN112274183A (zh) * 2020-11-02 2021-01-29 李云莹 一种神经内科用脑部超声波治疗装置

Also Published As

Publication number Publication date
MX2022002022A (es) 2022-05-11
ZA202202863B (en) 2023-10-25
EP4013497A1 (en) 2022-06-22
JP2022544803A (ja) 2022-10-21
WO2021032643A1 (en) 2021-02-25
CA3144700A1 (en) 2021-02-25
US12331042B2 (en) 2025-06-17
CN114302881A (zh) 2022-04-08
KR20220047807A (ko) 2022-04-19
EP4013497C0 (en) 2023-10-04
BR112022002769A2 (pt) 2022-05-10
US20220324852A1 (en) 2022-10-13
EP4013497B1 (en) 2023-10-04
IL290540A (en) 2022-04-01
CL2022000320A1 (es) 2023-02-03
CN114302881B (zh) 2025-03-25

Similar Documents

Publication Publication Date Title
ES2729424T3 (es) Inhibidores de Rho cinasa
JP5423675B2 (ja) アゾール化合物
EP4013497B1 (en) Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions
US20230115515A1 (en) Pyrazolylpropanamide compounds and uses thereof for treatment of prostate cancer
CN110914253B (zh) 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
BR112016009488B1 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica
CN105579433A (zh) 用于预防和治疗炎症的Cryopyrin抑制剂
HK1208219A1 (en) (e)-n-(2-amino-phenyl)-3-{1-[4-(1-methyl-1h-pyrazol-4-yl)-benzenesulfonyl]-1h-pyrrol-3-yl}-acrylamide tosylate salt
BR112016010515B1 (pt) Uso de um composto derivado de glutarimida no tratamento de doenças eosinofílicas
CN107106696A (zh) 环孢菌素的喹啉偶联物
WO2012075678A1 (zh) 取代噻唑基吡唑并吡啶类化合物及其医药用途
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
CN118340787A (zh) 药物
ES2447740T3 (es) Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas
EP3568128B1 (en) Hsp90b n-terminal isoform-selective inhibitors
WO2010085799A2 (en) Compositions and method for the treatment of parkinson's disease
KR20030016222A (ko) 수술후 스트레스 예방ㆍ치료제
US8530453B2 (en) Compounds and methods for the treatment of pain and other diseases
EP3197474B1 (en) Inhibitors of nf kappa-b activity for treatment of diseases and disorders
WO2024141066A1 (zh) 具有jnk抑制活性的嘧啶类衍生物及其应用
CN109758459B (zh) 取代的吡啶的新用途
US20200317626A1 (en) Autotaxin inhibitors
WO2026033305A1 (en) Fused bicyclic heterocyclic derivatives as hdac inhibitors
KR100842351B1 (ko) 인돌 유도체를 유효성분으로 함유하는 암 예방 및 치료용약학적 조성물
CN120424013A (zh) 雄激素受体拮抗剂、药物组合物及其应用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period